Clinical Trial Update: STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency [Phase 1]

View source ↗

Summary

Phase 1 trial update showing completion of a study evaluating STA-5326 Mesylate for gut inflammation in people with Common Variable Immunodeficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency

Drugs mentioned

• STA-5326 Mesylate (STA-5326 mesylate)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Common Variable Immunodeficiency | Phase 1 | Status: COMPLETED